- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making
Sikander Ailawadhi, MD, discusses how the 2024 ASH Annual Meeting’s “Prospective Patient Preference Study for BTKi Treatment Attributes in CLL and SLL” explored the factors influencing patient decision-making, revealing key treatment preferences and highlighting the importance of incorporating these insights into clinical practice when selecting BTK inhibitors for patients with CLL or SLL.
EP: 1.Unmet Needs and Emerging Trends in Hematologic Cancer Management Around ASH 2024
EP: 2.Insights on CLL and SLL Treatment with BTK Inhibitors: Patient Preferences and Shared Decision-Making
EP: 3.Insights on Multiple Myeloma Treatment: Real-World Data on Survivorship Burden and Patient Preferences
EP: 4.Insights on Allogeneic Hematopoietic Cell Transplantation: Values of Older Adult Patients
EP: 5.Advancing Hematologic Care and the Future of Shared Decision-Making
Video content above is prompted by the following:
- Discuss the data that was were presented at the 2024 ASH Annual Meeting titled in “Prospective Patient Preference Study for Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment Attributes and Factors Affecting Patient Shared Decision-Making in Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) in the United States (USA).”
- What was the objective of the study?
- How was this study designed/what methodology was used?
- What results were presented?
- What are your key takeaways from this study, and how does it change your perspective as a clinician when deciding between BTKis for patients with CLL or SLL?
Study Suggests Adding BTKi to Chemo May Improve Early Outcomes in Richter Transformation in CLL
December 18th 2025The study suggests that adding a Bruton tyrosine kinase inhibitor (BTKi) to frontline chemoimmunotherapy in Richter transformation improved complete response rates and progression-free survival compared with chemoimmunotherapy alone, though overall survival benefits remained unclear.
Read More
